companiesCompany
Triumvira Immunologics
aka Triumvira Immunologics, Inc.
Triumvira Immunologics is a Texas and Ontario cell-therapy company whose T-cell antigen coupler (TAC) engages the natural T-cell receptor rather than a CAR; TAC01-CLDN18.2 targets stomach and pancreatic cancers.
Overview
Triumvira Immunologics, with operations in Austin and Hamilton, Ontario, develops T-cell antigen coupler therapies in which an antigen-binding domain is coupled to the endogenous T-cell receptor complex, aiming for the potency of CAR-T with less toxicity. TAC01-HER2 was its first solid tumour programme and TAC01-CLDN18.2 targets Claudin 18.2 in gastric, gastro-oesophageal junction and pancreatic cancers in a phase 1/2 trial.
Headquarters
Austin, Texas, US
Scorecard
All companies#415of 1181 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
cell therapy
Website